- AstraZeneca antibody cocktail slashes risk of symptomatic COVID-19, setting up regulatory filings and a lifeline for the immunosuppressed
- After Aduhelm fallout, FDA veteran Woodcock out of running for commish job: report
- Despite upbeat tones from analysts, Fate Therapeutics' stock drops on blood cancer readout
- Sponsored: Artificial Intelligence in Drug Discovery Requires Validated Data
- China's Abogen raises $700M series C for mRNA trials, catapulting itself into the big leagues
- Migraine market better make way for AbbVie, as oral preventive atogepant poised to slice off $1.2B in sales
- Cerner taps Google, Geisinger vet Feinberg as new CEO
- CRISPR pioneer Feng Zhang's latest work delivers mRNA, gene therapy with a human protein
- Illumina completes Grail acquisition, regulators be damned
- J&J CEO Gorsky to step aside, handing reins of world's largest pharma to COVID-19 navigator Duato
- Fierce Pharma Asia—China mRNA specialist's $700M raise; Lilly-Innovent's Tyvyt win; XtalPi's AI financing
- Chutes & Ladders—J&J CEO Gorsky to step aside, handing world's largest pharma to COVID-19 navigator Duato
Featured Story | By Nick Paul Taylor AstraZeneca has caught a break. After enduring a series of struggles in COVID-19, the drugmaker has shown its long-acting antibody cocktail cuts the risk of symptomatic coronavirus infection by 77%, boosting its effort to provide protection to people underserved by vaccines. read more |
| |
|---|
|
Top Stories By Ben Adams Janet Woodcock, M.D., has spent more than three decades at the FDA, but her time running the agency as its interim leader is looking less likely to materialize into a full-time gig. read more By Ben Adams Fate Therapeutics saw its shares in the red after-hours Thursday night as durability concerns cast a shadow over its latest blood cancer data drop. read more Sponsored By: BioIVT Machine-learning-based techniques in drug and diagnostic discovery require copious amounts of biomedical data, and that data needs to be validated to ensure success. read more By Nick Paul Taylor Abogen Biosciences has raised one of the largest private biotech funding rounds ever. The low-profile biotech reeled in more than $700 million to advance its late-phase COVID-19 jab, obliterating the fundraising record for a Chinese mRNA vaccine developer. read more By Annalee Armstrong One of the gems AbbVie inherited from the $63 billion Allergan transaction is ready to take a slice of the highly competitive migraine market—and no, it’s not Botox. The New England Journal of Medicine published results from a phase 3 clinical trial of atogepant for preventing migraines Thursday. read more By Heather Landi David Feinberg, who spent the past two years at Google leading the tech giant's health efforts, is moving over to lead Cerner after a three-month CEO search. read more By Angus Liu COVID-19 mRNA vaccines and existing gene therapies, including those built with the CRISPR-Cas9 gene-editing tool, are delivered into cells with viral vectors or lipid nanoparticles. A research team led by CRISPR pioneer Feng Zhang of the Broad Institute has developed a new mRNA delivery system that harnesses a human protein called PEG10. read more By Conor Hale Despite looming antitrust investigations on both sides of the Atlantic, Illumina has pushed forward with its $8 billion deal to acquire Grail, maker of a newly launched blood test to detect dozens of different cancers. read more By Angus Liu Johnson & Johnson is switching captain to lead the world’s largest pharma company by 2020 revenue. Nine-year CEO Alex Gorsky will hand the helm to vice chairman of executive committee and leader of its COVID-19 response group, Joaquin Duato, early 2022. read more By Angus Liu A little-known Chinese mRNA specialist has raised $700 million to advance a COVID-19 vaccine candidate. Eli Lilly and Innovent Biologics tout a PD-1 win in stomach cancer. AI-powered drug discovery firm XtalPi has collected $400 million in financing. And more. read more By Kyle LaHucik The world's largest pharma will get a new face in January as CEO Alex Gorsky hands the reins to COVID-19 navigator Joaquin Duato. As Novavax gears up for a hopeful FDA emergency use authorization of its COVID-19 vaccine, the company hired ex-Sanofi global quality external affairs leader Nasir Egal, Ph.D., as senior vice president of quality assurance. And, after a $13.1 billion merger with Bristol Myers Squibb, MyoKardia's clinical operations leader is taking on the same duties at Esker Therapeutics. read more Resources Sponsored by: XIFIN inc. Download Frost & Sullivan’s enabling technologies best practices report to learn more about the four core functionalities required in successful precision medicine programs. Sponsored by: Patheon by Thermo Fisher Scientific Learn how a decentralized clinical trial strategy improves patient recruitment, reduces drop-out rates, and ultimately streamlines the path to the next trial phase. Sponsored by: Patheon by Thermo Fisher Scientific Learn how to build a robust packaging strategy and the key technical considerations in packaging design and operational planning to enable rapid commercialization of pharmaceuticals. Sponsored by: Patheon by Thermo Fisher Scientific Learn how regulations are changing and key considerations for commercializing cell and gene therapies without sacrificing quality. Sponsored By: LabVantage Solutions, Inc. Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
